Ivermectin for Cancer

The Bottom Line

Ivermectin is an FDA-approved antiparasitic (for river blindness, scabies, and parasitic worms) that has shown remarkable anticancer activity in laboratory studies. It kills cancer cells through multiple mechanisms: inhibiting the Wnt/beta-catenin pathway, suppressing PI3K/Akt/mTOR signaling, targeting cancer stem cells, and reversing drug resistance. It is one of the most active compounds in our preclinical screening database. The problem: achieving the anticancer concentrations seen in test tube studies may not be safely achievable in humans at standard doses. There are almost no completed cancer-specific clinical trials. Ivermectin is worth watching but is not yet actionable as a standalone cancer treatment.

What It Is

Ivermectin is a macrolide antiparasitic discovered in the 1970s and derived from soil bacteria (Streptomyces avermitilis). It won the 2015 Nobel Prize in Medicine for its transformative impact on river blindness and other parasitic diseases affecting hundreds of millions of people globally. It is on the WHO Essential Medicines List. In humans, ivermectin works by binding to glutamate-gated chloride channels in invertebrate nerve and muscle cells —-parasites are paralyzed and die. Mammalian cells have different chloride channels and are largely unaffected at therapeutic doses, which is why ivermectin is so safe as an antiparasitic.

How It Works Against Cancer

Despite being designed to target parasite-specific pathways, ivermectin interacts with multiple cellular targets that are relevant to cancer growth and survival:

• Wnt/beta-catenin inhibition: Ivermectin suppresses the Wnt/beta-catenin signaling pathway, which is constitutively active in many cancers (colorectal, breast, hepatocellular, melanoma). Wnt drives cell proliferation and stemness.
• PI3K/Akt/mTOR suppression: One of the most important oncogenic pathways. Ivermectin inhibits this signaling cascade, blocking cancer cell growth and survival.
• PAK1 kinase inhibition: PAK1 is a master regulator of multiple cancer-promoting pathways. Ivermectin is a potent PAK1 inhibitor — this is considered its most important anticancer mechanism.
• STAT3 inhibition: STAT3 is a transcription factor active in many tumors that promotes proliferation and immune evasion.
• Cancer stem cell (CSC) targeting: Perhaps the most exciting aspect — ivermectin appears to selectively target cancer stem cells, the slow-dividing cells responsible for tumor recurrence and metastasis. This is extremely rare in any anticancer agent.
• Multidrug resistance (MDR) reversal: Ivermectin inhibits P-glycoprotein, the pump that cancer cells use to eject chemotherapy drugs. This could resensitize resistant tumors to standard treatment.
• Anti-angiogenesis: Reduces VEGF expression, starving tumors of blood supply.
• Mitochondrial dysfunction and ROS: Induces oxidative stress selectively in cancer cells.
• Induces autophagic cell death: An alternative cell death pathway distinct from apoptosis.

The Evidence

Preclinical Data — Exceptionally Broad and Strong

Ivermectin's anticancer activity has been documented across an extraordinary range of cancer types in test tube and animal studies:

• Breast cancer (especially triple-negative): Among the strongest data. Ivermectin suppresses TNBC cell growth, migration, and invasion. Synergistic with paclitaxel in some models.
• Glioblastoma: Crosses the blood-brain barrier and shows activity against GBM stem cells.
• Colorectal cancer: Wnt pathway inhibition is particularly relevant here.
• Leukemia: Strong activity against chronic myeloid leukemia cells.
• Ovarian, gastric, hepatocellular, renal, prostate, lung, nasopharyngeal, melanoma: All have peer-reviewed preclinical evidence of ivermectin activity.

A 2020 comprehensive review (PMC7505114) and 2025 update (PMC12566834) catalogued this extensive body of work.

Combination Approaches — Most Promising Direction

Ivermectin shines brightest as a sensitizer/adjunct rather than monotherapy:

• With chemotherapy: Ivermectin reverses P-glycoprotein-mediated drug resistance, potentially resensitizing tumors to Taxol, doxorubicin, and other drugs.
• With immunotherapy: Emerging evidence suggests ivermectin may enhance checkpoint inhibitor efficacy.
• With other repurposed drugs: Peer-reviewed protocol published (2024) combining ivermectin + mebendazole + fenbendazole. Results pending.
• With rMETase (2025): Novel study showed synergistic eradication of pancreatic cancer cells in vitro.

Human Clinical Data — Almost Nonexistent

This is the critical gap. Despite enormous preclinical interest, there are almost no completed human trials specifically for ivermectin in cancer. A few Phase I trials have been registered but results have not been published. The challenge is whether the concentrations needed for anticancer effect (5-20 micromolar in vitro) can be safely achieved in humans at tolerable doses.

Evidence Grade: C — Early / Limited

The preclinical data is genuinely impressive — broad activity, multiple mechanisms, kills cancer stem cells, reverses drug resistance. This is not fringe science; the work is published in peer-reviewed journals. But the leap from test tube to human benefit has not been made. The outstanding question is whether ivermectin can achieve therapeutic concentrations at tolerable doses. Watch for clinical trial results. Not yet ready for standalone use.

Protocol Considerations

• Standard antiparasitic dose: 200 micrograms/kg as a single dose (for parasitic infection). This dose is very safe but almost certainly too low for anticancer effect.
• Reported cancer protocols (anecdotal): 1mg/kg daily or every other day — this is 5x the standard dose. Safety at this level for cancer is unestablished.
• Combination: Most rational approach is as an adjunct to standard treatment, not monotherapy.
• With mebendazole: Some protocols combine ivermectin with mebendazole (another antiparasitic with anticancer activity) — similar mechanisms but different targets.

Risks and Limitations

• Concentration challenge: The doses that kill cancer cells in vitro may not be safely achievable in humans
• Neurotoxicity: At higher doses, potential for CNS effects (especially with compromised blood-brain barrier)
• Drug interactions: Substrate of CYP3A4 and P-glycoprotein — potential for numerous interactions
• Liver toxicity: Hepatotoxicity possible at higher doses
• No established cancer protocol: There is no clinically validated dosing regimen for ivermectin in cancer treatment

Our Assessment

Ivermectin is one of the most scientifically interesting compounds in our entire review. The breadth of preclinical activity across cancer types, the multi-target mechanisms, the cancer stem cell targeting, and the drug resistance reversal properties make it genuinely compelling. The fact that it is a Nobel Prize-winning, WHO-essential, FDA-approved drug with an extraordinary safety record at antiparasitic doses makes it an unusually low-risk experimental approach. The critical unanswered question is whether the concentrations needed for anticancer effect are achievable in humans. Until clinical trial data clarifies this, ivermectin is best considered as a sensitizing agent to add to standard therapy, not a standalone treatment.

Sources

• PMC7505114 — "Ivermectin, a potential anticancer drug derived from an antiparasitic drug" (2020 comprehensive review)
• PMC12566834 — Review of chemical properties and therapeutic potential (2025)
• PMC11008553 — "Ivermectin: A Multifaceted Drug" (2024)
• PubMed 40715995 — "Should Healthcare Providers Caution or Explore?" (2025)
• PMC10137390 — Ivermectin in breast cancer (2023)
• PMC9033112 — Glioblastoma and CNS cancer applications